UPDATE 1-Actelion raises guidance as Q1 earnings beat consensus

April 21, 2015 5:55 AM

3 0

ZURICH, April 21 (Reuters) - Actelion Ltd, Europe's biggest biotech firm, raised its full-year guidance on Tuesday after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts' estimates.

The Swiss drugmaker has a dominant position in treatments for pulmonary arterial hypertension (PAH) and is banking on its new drug for the condition, Opsumit, to help cut its dependence on its original blockbuster Tracleer, which loses patent protection this year.

Also read: Novartis says Q3 profit slipped 4 percent, hurt by Alcon

Read more

To category page